Biomarin Pharmaceuticals (BMRN) said Tuesday that an experimental gene therapy targeting hemophilia A continued to help patients produce a protein enabling blood to clot. And while that will allow the company to seek accelerated approval in the U.S and Europe, data about Biomarin’s “one-and-done” treatment raise a big question: Do its effects last?
With gene therapy, a virus is used to insert genetic material to counter the effects of a disease. In hemophilia A, the most common form of the bleeding disorder, patients are missing a protein called factor VIII, which enables the blood to clot. The BioMarin treatment, valoctocogene roxaparvovec (for short: “valrox”), aims to enable patients to make their own factor VIII, so that they don’t need the extremely expensive drugs used to treat the disease.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Authors
